科研日历

订阅

MedSci主页 / 所有栏目 / 科研日历

52. 关于肿瘤领域biomarker的研究有哪些Tips？

2021-11-06 MedSci原创 MedSci原创

关注

梅斯医学-科研日历知识点_52

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2022-10-15 yige2011

    #TIPS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2022-05-24 cqlidoudou

    #marker#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2022-06-02 sunylz

    #Bio#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2022-04-19 vividelife

    #肿瘤领域#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2021-11-13 chengjn

    #iPS#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2021-11-13 1249857fm38暂无昵称

    #biomarker#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1643009, encodeId=b4651643009d0, content=<a href='/topic/show?id=131e1e4771a' target=_blank style='color:#2F92EE;'>#TIPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17477, encryptionId=131e1e4771a, topicName=TIPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99023051810, createdName=yige2011, createdTime=Sat Oct 15 18:25:53 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907384, encodeId=74c5190e384c4, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Tue May 24 09:25:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919337, encodeId=1070191933eae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jun 02 22:25:53 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069886, encodeId=07c52069886cb, content=<a href='/topic/show?id=17e78314284' target=_blank style='color:#2F92EE;'>#肿瘤领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83142, encryptionId=17e78314284, topicName=肿瘤领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Apr 19 05:25:53 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377794, encodeId=996b13e7794dc, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605321, encodeId=9eae16053218e, content=<a href='/topic/show?id=2df6344ef2' target=_blank style='color:#2F92EE;'>#biomarker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3447, encryptionId=2df6344ef2, topicName=biomarker)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53c919370539, createdName=1249857fm38暂无昵称, createdTime=Sat Nov 13 08:25:53 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069330, encodeId=fd77106933062, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Nov 11 18:29:28 CST 2021, time=2021-11-11, status=1, ipAttribution=)]
    2021-11-11 1207866fm50(暂无昵称)

    谢谢分享

    0